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Abstract 
Aims: To further wonder the influence of C-terminal residues on the pharmacological activities. Methods: 
The in vitro and in vivo opioid activities of C-terminal substitution analogs [L-Tic
4
] EM1 and [L-Tic
4
] 
EM2 were investigated using radioligand binding assay, guinea pig ileum (GPI) assay, mouse vas 
deferens (MVD) assay, systemic arterial pressure (SAP) assay and tail-flick test. Results: Our data 
showed that the analogs produced a higher į-opioid affinity but low ȝ-opioid affinity, dose-dependent but 
reduced analgesic activities and cardiovascular effect comparing with those of EMs. Moreover, these 
effects induced by the analogs can be inhibited by naloxone, indicating an opioid mechanism. Conclusion: 
These results provided suggestive evidences that the substitution of C-terminal residue may play an 
important role in the regulation of opioid affinities and pharmacological activities.  
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1. Introduction  
Endomorphin 1 (EM1) and endomorphin 2(EM2), the endogenous ȝ-opioid ligands discovered from 
bovine and human brain in 1997, display various of biological functions [1], albeit with some undesired 
side-effects, which limited their clinical use and encouraged the studies regarding the chemical 
modifications on the structures of EMs in order to improve the pharmacological profile of EMs [2-3]. 
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Among them, one hotspot attracting many attentions was the structure-activity relationship of C-terminal 
phenylalanine (Phe). Numerous studies demonstrated that Phe acts as an important element in 
determining opioid receptor binding affinity, however, the features that Phe is free to adopt a “bioactive” 
conformation at the receptor site and that activation can occur independently of the correct orientation and 
stereochemistry of this residue promote the studies of structure-activity of Phe [4]. In the past decades, a 
number of synthetic analogs have been developed with the aim to overcome these problems and confer to 
synthetic peptides advantages properties. Currently, our group has also synthesized a series of EMs 
analogs by substitution or modification of C-terminal residue to investigate the pharmacological effect of 
this residue [5-12]. In the present study, to further our knowledge of the influence of C-terminal 
substitution on the pharmacological activities, we have designed and synthesized the analogs of EMs with 
substitution of Phe4 by 1, 2, 3, 4 - tet -rahydroisoquinoline-3-carboxylic acid (Tic), meanwhile, 
radioligand binding assay, guinea pig ileum (GPI) assay, mouse vas deferens (MVD) assay, systemic 
arterial pressure (SAP) assay and tail-flick test have been performed to investigate the in vitro and in vivo 
opioid activities of these analogs. Our results gave the evidences that the substitution of C-terminal 
residue may play an important role in the regulation of opioid affinities and pharmacological activities.  
2. Results and Discussion 
Our previous study regarding the investigation of the conformational properties by 1D and 2D 1H 
NMR spectroscopy [8-9] and molecular modeling [11-12] provided suggestive evidences that the C-
terminal residue of EMs affected these analogs conformations markedly, therefore changed the opioid 
receptor affinity. In the study, to get insight into the important role of C-terminal residue of EMs, we 
investigated the analogs by substitution of the C-terminal residue by Tic. 
    With the purpose of revealing the relationship of structure and bioactivities, most efforts have been 
centered on the substitution side chain modification, backbone modification or deletion. Tic has been 
utilized as a conformationally restricted analogue of Phe and was established to be a synthon to enhance į 
receptor binding affinity and selectivity in many cases [13-14], which posses two potential advantages for 
replacing Phe in bioactive peptide ligands: constrainted peptide backbone conformation and restricted 
orientation of the aromatic side chain [14]. Our radio-ligand binding assay, GPI assay and MVD assay 
data showed the EMs analogues exhibited lower ȝ affinities but higher į affinity, revealing the 
transformation of selectivity of [L-Tic4]EMs from ȝ to į receptors (shown in Table 1 and 2). Intravenous 
injection (i.v.) injections of the two analogs in doses of 0.3-100nmol/kg can cause significant dose-
dependent decrease in SAP (Fig.1). The fact that the cardiovascular effects of analogs were inhibited by 
naloxone suggested opioid system is involved in the regulation of cardiovascular effect (Fig.2). 
Furthermore, the reduced affinity of [L-Tic4]EMs for ȝ-receptor made less influence on their 
cardiovascular effects thus the effect probably depend on their high affinity for į-opioid receptor. We also 
tested the well documented analgesic effects of the analogs via tail-flick test. These data shown in Fig. 3 
revealed that the analogs can produce a dose-dependent but short-lasting antinociceptive effect, probably 
owing to the much less receptors involved in the antinociception of [L-Tic4] EMs than that of EMs. 
Moreover, the antiociceptive effects can be inhibited by naloxone, indicating an opioid mechanism (data 
not shown). 
In conclusion, the results of the present study indicated that C-terminal substitution produced different 
pharmacological activies both in vitro and in vivo assays. It was noteworthy that the analogs exerted 
weaker antinociceptive effects, but decreased the undesirable cardiovascular side effects. These data gave 
the evidences that C-terminal residue was essential for opioid pharmacological activities of EMs analogs. 
The substitution of Phe4 by Tic may play an important role in the regulation of opioid affinities and 
activities. The present study would be helpful in the development of suitable ȝ-opioid or į-opioid 
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therapeutics. 
Table 1 Opioid Receptor Binding Affinities of EMs and [L-Tic4] EMs Analogues a 
Compounds Ki ± SE(nM)b Ki ± SE(nM)c Ki(į)/Ki(ȝ) 
EM1 4.55 ± 0.06 5093 ± 621 1119.3 
EM2 8.23 ± 0.15 >10,000 >1215 
[L-Tic4]EM1 1130.2 ± 126.5 634.4 ± 25.5 0.56 
[L-Tic4]EM2 4365.5 ± 325.1 831.8 ± 35.4 0.19 
a.values are the mean of 8 experiments ± S.E.M.
b. [3H]DAMGO   c. [3H]DPDPE 
Table 2 GPI And MVD Assay Data of Ems and  [L-Tic4] EMs 
Compounds 
IC50 ± SE (nM)a Ratio 
GPI (ȝ) MVD (į) MVD/GPI 
GPI/ 
MVD 
EM1 3.41 ± 0.3 47.40 ± 9.75 13.9 0.072 
EM2 5.68 ± 1.44 23.30 ± 6.57 4.102 0.244 
[L-Tic4]EM1 268.99 ± 23.68 18.59 ± 11.80 0.069 14.47 
[L-Tic4]EM2 934.85 ± 61.75 3.44 ± 2.38 0.004 271.84 
a. values are the mean of 8 experiments ± S.E.M. 
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Figure 1. Bar graphs comparison decrease of SAP and HR in response to i.v. injections of [L-Tic4]EMs in anethetized rat (n = 4–
6).The decrease of SAP and HR induced by [L-Tic4] EMs in different doses (a, b), values are shown as the Means ± S.E.M. Double 
asterisk (**) represent very significant results (p<0.01) in comparison with the control. 
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Figure 2. Antagonism by Naloxone of the Vasorelaxant Effect (%Relaxation) 
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Figure 3. The Antinociceptive Effect of [L-Tic4] EMs on the Nociceptive threshold measured by Tail-Flick Test in mice. The results 
are presented as % of the Maximal Positive Effect (MPE). 8–10 animals were used at each dose level, asterisk (*) represent 
significant results (p<0.05) in comparison with the control. 
Acknowledgements 
This work was supported by grants from the National Natural Science Foundation of China 
(No20772052) and grants from the Starting Funds for Doctors in Shaanxi University of Science and 
Technology (No.BJ10-13). 
References 
[1] Zadina JE, Hackler L, Ge LJ, Kastin AJ. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 
1997;386:499–502. 
[2] Kruszynski R, Fichna J, do-Rego JC, Janecki T, Kosson P, Pakulska W, et.al. Synthesis and biological activity of N-
methylated analogs of endomorphin-2. Bioorg. Med. Chem. 2005;13:6713–17. 
[3] Tömböly C, Kövér KE, Péter A,  Tourwé D, Biyashev D,  Benyhe S, et.al. Structure-activity study on the Phe side chain 
arrangement of endomorphins using conformationally constrained analogues. J. Med. Chem. 2004;47:735–43. 
553Pin Gong et al. / Procedia Environmental Sciences 8 (2011) 549 – 553
[4] Paterlini MG, Avitabile F, Ostrowski BG, Ferguson DM, Portoghese PS. Stereochemical requirements for receptor 
recognition of the mu-opioid peptide endomorphin-1. Biophys. J. 2000;78:590–599. 
[5] Zhao QY, Chen Q, Yang DJ, Feng Y, Long Y, Wang R,et.al. Endomorphin 1[psi] and endomorphin 2[psi], endomorphins 
analogues containing a reduced (CH2NH) amide bond between Tyr1 and Pro2, display partial agonist potency but significant 
antinociception. Life Sci. 2005;77:1155–1165. 
[6] Yu Y, Wang CL, Cui Y, Fan YZ, Liu J, Shao X,et al. C-terminal amide to alcohol conversion changes the cardiovascular 
effects of endomorphins in anesthetized rats. Peptides 2006;27:136–143. 
[7] Yu Y, Shao X, Cui Y, Liu HM, Wang CL, Fan YZ, et al. Structure-activity study on the spatial arrangement of the third 
aromatic ring of endomorphins 1 and 2 using an atypical constrained C terminus. Chem Med Chem 2007,2:309–17. 
[8] Shao X, Gao YF, Zhu CJ, Liu XH, Yao JL, Cui YX, et al. Conformational analysis of endomorphin-2 analogs with 
phenylalanine mimics by NMR and molecular modeling. Bioorg  Med Chem 2007;15:3539–47. 
[9] Wang CL, Yao JL, Yu Y, Shao X, Cui Y, Liu HM, et al. Structure-activity study of endomorphin-2 analogs with C-
terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem, 2008;16:6415–22. 
[10] Wang CL, Guo C, Zhou Y , Wang R. In vitro and in vivo characterization of opioid activities of C-terminal esterified 
endomorphin-2 analogs. Peptides2009;30:1697–1704. 
[11] Liu X, Kai M, Jin L, Wang R. Computational study of the heterodimerization between mu and delta receptors. J. Comput. 
Aided Mol. Des 2009; 23:321. 
[12] Liu X, Kai M, Jin L, Wang R. Molecular modeling studies to predict the possible binding modes of endomorphin analogs 
in mu opioid receptor. Bioorg  Med Chem Let 2009; 19:5387–91. 
[13] Kyle DJ, Martin JA, Burch RM, Carter JP, Lu SF, Meeker S,et al. Probing the bradykinin receptor: mapping the geometric 
topography using ethers of hydroxyproline in novel peptides. J. Med. Chem. 1991;34:2649–53. 
[14] Tancredi T, Salvadori S, Amodeo P, Picone D, Lazarus LH, Bryant SD, et al. Conversion of enkephalin and dermorphin 
into delta-selective opioid antagonists by single-residue substitution. Eur. J. Biochem. 1994;224:241–247. 
 
